Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study

Conrad Rauber⁎, Shilpa Tiwari-Heckler⁎, Jan Pfeiffenberger⁎, Arianeb Mehrabi⁎, Frederike Lund‡, Philip Gathi⁎, Markus Mieth⁎, Uta Merle⁎, and Christian Rupp⁎

⁎Department for Gastroenterology and Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany; †Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany; ‡Department of Anesthesiology, University Hospital Heidelberg, Heidelberg, Germany; and §Department for Gastroenterology, Städtisches Klinikum Ludwigshafen, Ludwigshafen, Germany

ABSTRACT

Background. In liver transplant (LT) recipients with severe coronavirus disease 2019 (COVID-19), fatal outcome has been reported in a substantial subset of patients. Whether LT recipients are at increased risk for severe COVID-19 compared with the general population is controversial. Here we report the results of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in a large LT recipient cohort.

Methods. A total of 219 LT recipients were enrolled between May 5, 2020, and August 6, 2020, at the University Hospital Heidelberg. Serum blood samples were collected and tested for anti-SARS-CoV-2 IgG. SARS-CoV-2 RNA was detected in nasopharyngeal swabs using reverse transcription–polymerase chain reaction assays.

Results. Taking into account known risk factors of arterial hypertension, obesity, diabetes, or leukopenia, LT recipients a priori represented a high-risk cohort for severe COVID-19 with 101 of 219 (46.1%) presenting with more than 2 risk factors for severe COVID-19. Out of 219 LT recipients, 8 (3.7%) either had a positive test result for nasopharyngeal SARS-CoV-2 RNA or anti–SARS-CoV-2 serum IgG. SARS-CoV-2 RNA was detected in nasopharyngeal swabs using reverse transcription–polymerase chain reaction assays.

Conclusions. In summary, LT recipients showed a SARS-CoV-2 seroconversion rate similar to that of the general population with a substantial percentage of unrecognized infections.

Liver transplant (LT) recipients are a patient group vulnerable to severe infections due to immunosuppression. Early published case series in LT and solid organ transplant (SOT) recipients with coronavirus disease 2019 (COVID-19) reported a high fatality rate of up to 30%, exceeding the rate of the general population [1–4]. In contrast, a more recent Swiss case study and an international registry study found mortality rates comparable to those of comorbidity-matched non–transplant recipients [5,6]. Initial symptoms of patients with COVID-19 are diverse [7]. Patients who have a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be asymptomatic or can develop COVID-19, and in severe cases, their condition may deteriorate due to acute respiratory distress syndrome with subsequent respiratory failure and death [8]. Both among the general
population and among SOT recipients, the main risk factors for severe COVID-19 were older age and comorbidities such as diabetes, obesity, and renal and cardiopulmonary disease [9–12]. Data on immunosuppression as a risk factor for COVID-19 are inconclusive, but minimization of immunosuppression has been widely recommended for LT patients with COVID-19 on the basis of experience with other respiratory pathogens [13]. LT patients in most centers are therefore counseled to strictly follow hygiene and lifestyle precautions to avoid SARS-CoV-2 infection [14]. It is not known to what extent this advice is effective to reduce SARS-CoV-2 infection in the LT recipient population. The present study aimed to define the incidence and prevalence of SARS-CoV-2 infection and to explore the (preventive) effect of personal behavioral adjustments among LT recipients.

**METHODS**

**Study Design**

This prospective study was conducted between May 5, 2020, and August 6, 2020, at the University Hospital Heidelberg, located in the German state of Baden-Württemberg. All study participants had undergone LT in the past and were older than 18 years of age. All study participants provided written informed consent before enrollment. The study was approved by the ethics committee of the Medical Faculty of the University of Heidelberg (approval number S-457/2020). The study was conducted in accordance with good clinical practice principles and the Declaration of Helsinki.

**Sampling and Procedures**

Study enrollment was performed when patients presented for scheduled routine follow-up after LT. Routine follow-up on an outpatient basis is performed at least every 6 months at our center. After patients provided written informed consent, their serum blood samples were collected between May 5 and August 6, 2020. Blood was centrifuged, and serum was stored until analysis (−80°C). Analyses were performed in batches at the University Hospital Heidelberg. Anti–SARS-CoV-2 IgG (EUROIMMUN) was determined with enzyme-linked immunosorbent assays (ELISAs). The manufacturer’s data sheet (April 29, 2020) reports cross-reactivities with anti–SARS-CoV-1 IgG antibodies, but not with Middle East respiratory syndrome coronavirus, human coronavirus (HCoV)-229E, HCoV-NL63, HCoV-HKU1, or HCoV-OC43 IgG antibodies. Manufacturer-reported sensitivity and specificity were 94.6% and 99.8%, respectively. Routine pharyngeal and nasal SARS-CoV-2 swabbing was performed on 126 patients between May 5, 2020, and July 5, 2020. Thereafter, routine SARS-CoV-2 screening was terminated because general population infection rates were very low. Nasopharyngeal swabs underwent nucleic acid amplification testing (reverse transcription–polymerase chain reaction [RT-PCR]) on the same day to confirm SARS-CoV-2 infection in certified test laboratories at University Hospital Heidelberg. For diagnosis of SARS-CoV-2, RNA was isolated from nasopharyngeal and oropharyngeal swab specimens using QIAGEN kits (QIAGEN, Hilden, Germany), automated on the QIASymphony (DSP Virus/Pathogen Mini Kits) or QIAcube (QIAamp Viral RNA Mini Kits) devices, and eluted in 115 μL of elution buffer.

RT-PCR was carried out using various reagent mixes according to the manufacturers’ instructions: LightMix Modular SARS and Wuhan CoV E-gene, LightMix Modular SARS and Wuhan CoV N-gene, LightMix Modular Wuhan CoV RdRP-gene, and LightMix Modular EAV RNA Extraction Control (as an internal control) from TIB MOLBIOL Syntheselabor GmbH (Berlin, Germany) and the LightCycler Multiplex RNA Virus Master (Roche, Mannheim, Germany). RT-PCR was performed on LightCycler 480 or 480 II (Roche). Additionally, 104 patients

| Table 1. Clinical Characteristics |
|----------------------------------|
| Characteristics                  | All Patients (N = 219) | SARS-CoV-2–Positive Patients (n = 8) | P Value |
|----------------------------------|------------------------|-------------------------------------|---------|
| Sex, female, n (%)               | 89 (40.6%)             | 56.7 (25.5-69.5)                     | ns      |
| Age, years (median, range)       | 56.9 (18.1-78.2)       | 6.4 (0.1-30.0)                      | ns      |
| Sex, female, n (%)               | 89 (40.6%)             | 56.7 (25.5-69.5)                     | ns      |
| >65 years                        | 44 (20.8%)             | 2 (25.0%)                           | ns      |
| Interval from LT, years          | 6.4 (0.1-30.0)         | 6.5 (0.2-15.0)                      | ns      |
| Indication for LT                |                        |                                     |         |
| Alcohol                          | 42 (19.2%)             | 0 (0.0%)                            | ns      |
| Hepatitis B                      | 9 (4.1%)               | 1 (12.5%)                           | ns      |
| Hepatitis C                      | 10 (4.6%)              | 0 (0.0%)                            | ns      |
| HCC                              | 43 (19.6%)             | 2 (25.0%)                           | ns      |
| PSC                              | 26 (11.9%)             | 0 (0.0%)                            | ns      |
| Others                           | 79 (36%)               | 5 (62.5%)                           | ns      |
| Comorbidities                    |                        |                                     |         |
| BMI, kg/m² (mean, SD)            | 25.6 (15.8-46.0)       | 22.9 (20.0-32.2)                     | ns      |
| <25                              | 97 (44.3%)             | 5 (62.5%)                           | ns      |
| 25-30                            | 74 (33.8%)             | 1 (12.5%)                           | ns      |
| >30                              | 48 (21.9%)             | 2 (25%)                             | ns      |
| Cardiovascular                   |                        |                                     |         |
| disease                          | 21 (9.6%)              | 0 (0.0%)                            | ns      |
| Respiratory disease              |                        |                                     |         |
| disease                          | 108 (49.3%)            | 5 (62.5%)                           | ns      |
| Diabetes                         | 66 (30.1%)             | 2 (25.0%)                           | ns      |
| Active cancer                    | 3 (1.4%)               | 0 (0.0%)                            | ns      |
| Active smoking                   | 19 (8.7%)              | 0 (0.0%)                            | ns      |
| Leukopenia                       | 50 (22.8%)             | 2 (25%)                             | ns      |
| RAAS inhibitor                   | 56 (25.6%)             | 1 (12.5%)                           | ns      |
| use                              |                        |                                     |         |
| Renal insufficiency              |                        |                                     |         |
| Dialysis                         | 11 (5.0%)              | 2 (25%)                             | .02     |
| GFR <30 mL/ min                  | 17 (7.7%)              | 2 (25%)                             | .02     |
| GFR 30-60 mL/ min                | 43 (19.6%)             | 2 (25%)                             | .02     |
| GFR <60 mL/ min                  | 159 (72.6%)            | 4 (50%)                             | .02     |
| Immunosuppression                |                        |                                     |         |
| Tacrolimus                       | 140 (63.9%)            | 5 (62.5%)                           | ns      |
| Cyclosporine                     | 42 (19.2%)             | 2 (25%)                             | ns      |
| mTOR inhibitor                   | 54 (24.7%)             | 2 (25%)                             | ns      |
| MMF/MPA                          | 97 (44.3%)             | 4 (50%)                             | ns      |

Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; HCC, hepatocellular carcinoma; LT, liver transplant; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; PSC, primary sclerosing cholangitis; RAAS, renin-angiotensin-aldosterone system; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
Table 2. SARS-CoV-2 Test Results

| SARS-CoV-2 RNA | Anti-SARS-CoV-2 IgG Negative | Anti-SARS-CoV-2 IgG Positive | Total |
|----------------|-----------------------------|-----------------------------|-------|
| Negative       | 211 (96.3%)                 | 6 (2.7%)                    | 217 (99.0%) |
| Positive       | 1 (0.5%)                    | 1 (0.5%)                    | 2 (1.0%)  |

Total 212 (96.8%) 7 (3.2%)

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

1114 RAUBER, TIWARI-HECKLER, PFEIFFENBERGER ET AL

Table 3. Clinical Patient Details

| Patient No. | Sex | RNA | Age (Years) | Time Since LT (Years) | Clinical Symptoms | Dialysis | Hypertension | Diabetes | BMI (kg/m²) | Immunosuppression |
|-------------|-----|-----|-------------|-----------------------|------------------|----------|--------------|----------|-------------|-------------------|
| 1           | F   | +   | 25          | 0.5                   | Fever, dry cough, fatigue | No        | No           | No       | 23          | Tac/MMF           |
| 2           | F   | +   | 51          | 6.8                   | Dry cough         | Yes       | Yes          | No       | 30          | Cic               |
| 3           | M   | –   | 62          | 0.2                   | Dry cough, fever  | No        | Yes          | Yes      | 30          | Tac/MMF           |
| 4           | M   | +   | 60          | 3.6                   | None              | No        | Yes          | Yes      | 32          | Tac/mTOR          |
| 5           | F   | –   | 51          | 6.2                   | None              | No        | Yes          | No       | 22          | Tac/MMF           |
| 6           | M   | –   | 67          | 7.4                   | None              | No        | No           | No       | 20          | Tac/MMF           |
| 7           | M   | –   | 52          | 14.6                  | None              | No        | No           | No       | 23          | Tac               |
| 8           | F   | –   | 69          | 15.0                  | None              | Yes       | Yes          | Yes      | 21          | mTOR              |

Abbreviations: BMI, body mass index; Cic, ciclosporin; LT, liver transplant; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin; Tac, tacrolimus.
medical visits (Fig 3A-F). Most commonly worn face masks were surgical masks (47.5%), cloth masks (31.7%), and FFP2 filtering facepiece masks (20.8%) (Fig 3G). All patients always wore masks in supermarkets and in hospitals, and 16.3% always wore masks outside.

**DISCUSSION**

We performed a prospective screening trial for SARS-CoV-2 RNA and anti-SARS-CoV-2 IgG infection in LT recipients during the COVID-19 pandemic in southern Germany. We documented acute or past SARS-CoV-2 infection in 3.7% of our LT recipients during the study, which is in line with prior reports [15]. Although direct serosurveys in the general population are lacking for our study region, the SARS-CoV-2 infection percentage in the population can be roughly estimated from serosurvey studies in other regions with similar health care settings. Until study termination, about 37,000 PCR-proven SARS-CoV-2 infections had been documented in the study area (Baden-Württemberg). Recent German serosurveys provide a rough estimate of a factor of 4–10 of PCR-documented SARS-CoV-2 infections to overall serology-proven infections, proposing a seroprevalence of 1.3%–3.2% in southwestern Germany [16,17]. Taking into account this estimate, the prevalence of active or past SARS-CoV-2 infection in LT recipients is comparable to that in the general population. Our direct study was limited to 219 patients who presented for routine follow-up appointments after LT at our institution. However, the overall cohort comprises 1200 patients in the same region. These patients were encouraged to contact the transplant center in case of infection or hospital stay. Over the study period, we did not record a single case of hospitalization or death due to COVID-19 in this cohort. The presented data show an overall low but significant percentage of LT patients who had been infected with SARS-CoV-2. Five of 8 patients seroconverted without experiencing any clinical overt symptoms; in the other 3 of 8 patients, clinical symptoms were mild and self-limited. Interestingly, patient 2 (Table 3) had a positive screen for SARS-CoV-2 RNA but a negative

**Fig 1.** The course of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Germany. (A) Map of the Federal Republic of Germany indicating RNA-proven SARS-CoV-2 cases per capita in different federal states. Data as of August 15, 2020: red, >300 cases per 100,000; orange, 200-300 cases/100,000; yellow, 100-200 cases/100,000; green, <100 cases/100,000. Black dots indicate residence of enrolled LT recipients. (B) Number (7-day gliding average) of RNA-proven SARS-CoV-2 cases per day in the German state of Baden-Württemberg from February 25 until August 8, 2020. Below: Sample accrual time frame for nasopharyngeal RNA swab (upper black bar) and blood serum sample (lower black bar).

**Fig 2.** Anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) serum titers in patients 1 and 7 over time.
result for anti–SARS-CoV-2 IgG on multiple occasions afterward. About 90% of non-immunocompromised patients develop anti–SARS-CoV-2 IgG after infection [18].

The detailed cases of patients 1 and 3 (Table 3) with repetitive serum samples highlight the potential rapid loss of anti–SARS-CoV-2 IgG within a few weeks. The extent to which immunosuppression adds to the phenomenon could not be assessed, owing to the overall low case number.

We further assessed how LT recipients changed their personal behavior using a standardized questionnaire. Most LT recipients were aware of the risk of SARS-CoV-2 infection and protected themselves with face masks and avoided public places such as supermarkets or social gatherings. Although a control group is certainly missing, it is surprising that, despite the self-containment efforts in this patient cohort, the SARS-CoV-2 IgG seroprevalence was comparable to that in the general population. Examining detailed patient information highlights the role that health care–acquired infection might play. Five of 8 patients were hospitalized during the pandemic or underwent hemodialysis for chronic renal failure. We cannot rule out that these patients contracted SARS-CoV-2 infection in the health care setting and that the health care system itself poses an important risk for this comorbid patient group. Concordantly, health care visits were less strictly avoided than supermarkets or social contact (Fig 3).

The present study has several important limitations. First, overall recorded numbers of seroconversion in the LT recipient cohort remained low, and although the specificity of the antibody test is given as 99.8% by the manufacturer, we cannot rule out false-positive test results. However, all positive test results were in the high titer range. Second, the study size was insufficient to assess individual risk factors such as immunosuppression, and it remains an important research question whether immunosuppression exerts protective effects against severe COVID-19 in LT patients. Compared with other studies that have highlighted increased morbidity and mortality in LT recipients with COVID-19, our study was conducted in a health care setting that was at no point overwhelmed during the first wave of the pandemic. Risk for severe COVID-19 in LT recipients seems comparable to that of the general population, and COVID-19 morbidity was low in a large LT recipient cohort. However, only 3.2% had antibodies against SARS-CoV-2, leaving potentially 96.8% of the cohort susceptible to SARS-CoV-2 infection. We documented a fast decline of anti–SARS-CoV-2 antibodies in two LT recipients, questioning the durability of anti–SARS-CoV-2 immunity and emphasizing the importance of continued containment efforts to protect at-risk patient groups.

REFERENCES

[1] Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–8.
[2] Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020;20:1849–58.
[3] Becchetti C, Zambelli MF, Pasulo L, Donato MF, Iveruzzini F, Detty O, et al. COVID-19 in an international European liver transplant recipient cohort. Gut 2020;69:1832–40.
[4] Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020;5:643–4.

[5] Tschopp J, L’Huillier A, Mombelli M, Mueller N, Khanna N, Garzoni C, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant 2020;20:2876–82.

[6] Webb GJ, Marjot T, Cook IA, Aloman C, Armstrong MJ, Brenner EJ, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020;5:1008–16.

[7] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.

[8] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[9] Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020;368:m1198.

[10] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–38.

[11] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020;36:e3319.

[12] Sattar N, McMinn IB, McMurray J JV. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation 2020;142:4–6.

[13] Parente A, Manzia TM, Angelico R, Tiriotta F, Muiiesan P, Tisone G, et al. COVID-19, liver transplant, and immunosuppression: Allies or foes? Transpl Infect Dis [Internet]. 2020. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.13417. Accessed January 8, 2021.

[14] Ritschl PV, Nevermann N, Wiering L, Wu HH, Moroder P, Brandl A, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. Am J Transplant 2020;20:1826–36.

[15] Ossami Saidy RR, Glibke B, Pratschke J, Schoening W, Eirich D. Successful implementation of preventive measures leads to low relevance of SARS-CoV-2 in liver transplant patients: Observations from a German outpatient department. Transpl Infect Dis [Internet]. 2020. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.13363. Accessed November 9, 2020.

[16] Santos-Hövener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Eurosurveillance [Internet]. 2020;25(47). Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.47.2001752. Accessed January 8, 2021.

[17] Streeck H, Schulte B, Kümmerer B, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV2 in a super-spread event in Germany. Nat Commun 2020;11:5829.

[18] Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724–34.